Trade Eli Lilly & Co - LLY CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 2.49 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.030779% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.013666% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Eli Lilly and Co ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 330.39 |
Open* | 329.73 |
1-Year Change* | 31.38% |
Day's Range* | 329.73 - 341.12 |
52 wk Range | 231.87-384.44 |
Average Volume (10 days) | 3.96M |
Average Volume (3 months) | 58.70M |
Market Cap | 314.22B |
P/E Ratio | 47.91 |
Shares Outstanding | 950.18M |
Revenue | 28.54B |
EPS | 6.90 |
Dividend (Yield %) | 1.3668 |
Beta | 0.33 |
Next Earnings Date | Apr 27, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Feb 3, 2023 | 337.93 | 5.58 | 1.68% | 332.35 | 342.09 | 328.30 |
Feb 2, 2023 | 330.39 | -2.41 | -0.72% | 332.80 | 334.80 | 316.14 |
Feb 1, 2023 | 342.15 | 1.23 | 0.36% | 340.92 | 345.40 | 336.80 |
Jan 31, 2023 | 343.91 | 5.17 | 1.53% | 338.74 | 344.11 | 338.74 |
Jan 30, 2023 | 340.18 | -1.86 | -0.54% | 342.04 | 347.28 | 339.15 |
Jan 27, 2023 | 341.77 | -2.99 | -0.87% | 344.76 | 347.70 | 341.32 |
Jan 26, 2023 | 347.65 | -2.14 | -0.61% | 349.79 | 351.79 | 346.30 |
Jan 25, 2023 | 349.26 | 7.35 | 2.15% | 341.91 | 349.50 | 341.91 |
Jan 24, 2023 | 345.92 | -16.82 | -4.64% | 362.74 | 364.89 | 339.80 |
Jan 23, 2023 | 341.82 | -2.04 | -0.59% | 343.86 | 345.86 | 339.80 |
Jan 20, 2023 | 345.80 | 1.01 | 0.29% | 344.79 | 348.73 | 341.12 |
Jan 19, 2023 | 350.82 | 1.39 | 0.40% | 349.43 | 355.30 | 349.43 |
Jan 18, 2023 | 351.45 | -4.05 | -1.14% | 355.50 | 358.73 | 351.25 |
Jan 17, 2023 | 357.38 | -1.09 | -0.30% | 358.47 | 361.50 | 356.17 |
Jan 13, 2023 | 361.23 | 6.08 | 1.71% | 355.15 | 362.95 | 355.15 |
Jan 12, 2023 | 358.72 | 3.25 | 0.91% | 355.47 | 360.15 | 351.69 |
Jan 11, 2023 | 359.86 | 7.67 | 2.18% | 352.19 | 361.49 | 348.71 |
Jan 10, 2023 | 352.54 | 5.75 | 1.66% | 346.79 | 352.96 | 342.22 |
Jan 9, 2023 | 349.45 | -13.34 | -3.68% | 362.79 | 364.60 | 348.43 |
Jan 6, 2023 | 362.71 | 4.92 | 1.38% | 357.79 | 366.20 | 356.41 |
Eli Lilly & Co Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total revenue | 21222.1 | 19973.8 | 21493.3 | 22319.5 | 24539.8 | 28318.4 |
Revenue | 21222.1 | 19973.8 | 21493.3 | 22319.5 | 24539.8 | 28318.4 |
Cost of Revenue, Total | 5654.9 | 4447.7 | 4681.7 | 4721.2 | 5483.3 | 7312.8 |
Gross Profit | 15567.2 | 15526.1 | 16811.6 | 17598.3 | 19056.5 | 21005.6 |
Total Operating Expense | 17763.3 | 17970.5 | 17958.8 | 17287.9 | 18481.8 | 22366.5 |
Selling/General/Admin. Expenses, Total | 6452 | 5982.4 | 5975.1 | 6213.8 | 6121.2 | 6431.6 |
Research & Development | 5243.9 | 5096.2 | 5051.2 | 5595 | 6085.7 | 7025.9 |
Unusual Expense (Income) | 412.5 | 2444.2 | 2250.8 | 757.9 | 791.6 | 1596.2 |
Operating Income | 3458.8 | 2003.3 | 3534.5 | 5031.6 | 6058 | 5951.9 |
Interest Income (Expense), Net Non-Operating | -76.5 | -58.6 | -83.2 | -320.2 | -326.6 | -137.5 |
Other, Net | -8.3 | 360.1 | 228.8 | 554.5 | 1498.5 | 341.1 |
Net Income Before Taxes | 3374 | 2304.8 | 3680.1 | 5265.9 | 7229.9 | 6155.5 |
Net Income After Taxes | 2737.6 | 4493.6 | 3325.9 | 4637.9 | 6193.7 | 5581.7 |
Net Income Before Extra. Items | 2737.6 | 4493.6 | 3325.9 | 4637.9 | 6193.7 | 5581.7 |
Net Income | 2737.6 | -204.1 | 3232 | 8318.4 | 6193.7 | 5581.7 |
Income Available to Common Excl. Extra. Items | 2737.6 | 4493.6 | 3325.9 | 4637.9 | 6193.7 | 5581.7 |
Income Available to Common Incl. Extra. Items | 2737.6 | -204.1 | 3232 | 8318.4 | 6193.7 | 5581.7 |
Diluted Net Income | 2737.6 | -204.1 | 3232 | 8318.4 | 6193.7 | 5581.7 |
Diluted Weighted Average Shares | 1061.82 | 1052.02 | 1033.67 | 935.684 | 912.505 | 911.681 |
Diluted EPS Excluding Extraordinary Items | 2.5782 | 4.27139 | 3.21757 | 4.95669 | 6.78758 | 6.12243 |
Dividends per Share - Common Stock Primary Issue | 2.04 | 2.08 | 2.25 | 2.58 | 2.96 | 3.4 |
Diluted Normalized EPS | 2.89874 | 6.15171 | 5.37021 | 5.70063 | 7.63447 | 7.79951 |
Total Extraordinary Items | -4697.7 | -93.9 | 3680.5 | 0 | 0 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total revenue | 6805.6 | 6740.1 | 6772.8 | 7999.9 | 7810 |
Revenue | 6805.6 | 6740.1 | 6772.8 | 7999.9 | 7810 |
Cost of Revenue, Total | 1878.6 | 1953.2 | 1430.8 | 2050.2 | 2072.1 |
Gross Profit | 4927 | 4786.9 | 5342 | 5949.7 | 5737.9 |
Total Operating Expense | 5650.3 | 5336.7 | 5296.8 | 6082.7 | 5405.7 |
Selling/General/Admin. Expenses, Total | 1576 | 1685.7 | 1577.9 | 1592 | 1557.9 |
Research & Development | 1684.8 | 1672.8 | 1708.9 | 1959.4 | 1610.1 |
Unusual Expense (Income) | 510.9 | 25 | 579.2 | 481.1 | 165.6 |
Operating Income | 1155.3 | 1403.4 | 1476 | 1917.2 | 2404.3 |
Interest Income (Expense), Net Non-Operating | 219.2 | 133.9 | -323.4 | -167.2 | -503.3 |
Other, Net | 101.9 | 56.6 | 92.7 | 89.9 | 152.6 |
Net Income Before Taxes | 1476.4 | 1593.9 | 1245.3 | 1839.9 | 2053.6 |
Net Income After Taxes | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Net Income Before Extra. Items | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Net Income | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Income Available to Common Excl. Extra. Items | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Income Available to Common Incl. Extra. Items | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Diluted Net Income | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Diluted Weighted Average Shares | 912.4 | 910.4 | 910.8 | 911.624 | 906.4 |
Diluted EPS Excluding Extraordinary Items | 1.48542 | 1.52702 | 1.21882 | 1.89343 | 2.0994 |
Dividends per Share - Common Stock Primary Issue | 0.85 | 0.85 | 0.85 | 0.85 | 0.98 |
Diluted Normalized EPS | 2.02635 | 1.55448 | 1.80644 | 2.41408 | 2.28211 |
Total Extraordinary Items | 0 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Current Assets | 15101.4 | 19202.1 | 20549.6 | 13709.6 | 17462.1 | 18452.4 |
Cash and Short Term Investments | 6038.6 | 8034.1 | 7408.9 | 2438.5 | 3681.3 | 3908.6 |
Cash & Equivalents | 4582.1 | 6536.2 | 7320.7 | 2337.5 | 3657.1 | 3818.5 |
Short Term Investments | 1456.5 | 1497.9 | 88.2 | 101 | 24.2 | 90.1 |
Total Receivables, Net | 4766.3 | 5262.2 | 5776.8 | 5541.5 | 6929 | 8127.2 |
Accounts Receivable - Trade, Net | 4029.4 | 4546.3 | 5776.8 | 4547.3 | 5875.3 | 6672.8 |
Total Inventory | 3561.9 | 4458.3 | 3098.1 | 3190.7 | 3980.3 | 3886 |
Prepaid Expenses | 734.6 | 1447.5 | 2036.7 | 2538.9 | 2871.5 | 2530.6 |
Total Assets | 38805.9 | 44981 | 43908.4 | 39286.1 | 46633.1 | 48806 |
Property/Plant/Equipment, Total - Net | 8252.6 | 8826.5 | 7996.1 | 8405 | 8681.9 | 8985.1 |
Property/Plant/Equipment, Total - Gross | 16777.6 | 18091.1 | 16663 | 17566.6 | 18252.6 | 18961.8 |
Accumulated Depreciation, Total | -8525 | -9264.6 | -8666.9 | -9161.6 | -9570.7 | -9976.7 |
Goodwill, Net | 3972.7 | 4370.1 | 1366.6 | 3679.4 | 3766.5 | 3892 |
Intangibles, Net | 4357.9 | 4029.2 | 1068 | 6618 | 7450 | 7691.9 |
Long Term Investments | 5207.5 | 5678.8 | 2005.4 | 1962.4 | 2966.8 | 3212.6 |
Other Long Term Assets, Total | 1913.8 | 2874.3 | 10922.7 | 4911.7 | 6305.8 | 6572 |
Total Current Liabilities | 10986.6 | 14535.9 | 11888.1 | 11775.2 | 12481.6 | 15052.7 |
Accounts Payable | 1349.3 | 1410.7 | 1207.1 | 1405.3 | 1606.7 | 1670.6 |
Accrued Expenses | 896.9 | 997.9 | 955.6 | 915.5 | 997.2 | 958.1 |
Notes Payable/Short Term Debt | 1299.3 | 2696.8 | 498.9 | 1494.2 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 638.1 | 1009.8 | 603.3 | 5.1 | 8.7 | 1538.3 |
Other Current Liabilities, Total | 6803 | 8420.7 | 8623.2 | 7955.1 | 9869 | 10885.7 |
Total Liabilities | 24798.2 | 33388.8 | 34079.7 | 36679.2 | 40991.5 | 39826.8 |
Total Long Term Debt | 8367.8 | 9940.5 | 9196.4 | 13817.9 | 16586.6 | 15346.4 |
Long Term Debt | 8358.8 | 9931.8 | 9196.4 | 13817.9 | 16586.6 | 15346.4 |
Capital Lease Obligations | 9 | 8.7 | ||||
Minority Interest | 72.8 | 75.7 | 1080.4 | 92.2 | 183.6 | 175.6 |
Other Liabilities, Total | 5371 | 8836.7 | 10602.1 | 8806.4 | 9639.8 | 7518.4 |
Total Equity | 14007.7 | 11592.2 | 9828.7 | 2606.9 | 5641.6 | 8979.2 |
Common Stock | 688.5 | 687.9 | 661 | 598.8 | 598.2 | 596.3 |
Additional Paid-In Capital | 5640.6 | 5817.8 | 6583.6 | 6685.3 | 6778.5 | 6833.4 |
Retained Earnings (Accumulated Deficit) | 16046.3 | 13894.1 | 11395.9 | 4920.4 | 7830.2 | 8958.5 |
Treasury Stock - Common | -80.5 | -75.8 | -69.4 | -60.8 | -55.7 | -52.7 |
Unrealized Gain (Loss) | 224 | 113.5 | 4.9 | 14.8 | 3.7 | |
Other Equity, Total | -8511.2 | -8845.3 | -8742.4 | -9541.7 | -9524.4 | -7360 |
Total Liabilities & Shareholders’ Equity | 38805.9 | 44981 | 43908.4 | 39286.1 | 46633.1 | 48806 |
Total Common Shares Outstanding | 1100.88 | 1100.01 | 1057.64 | 957.526 | 956.59 | 953.653 |
Other Current Assets, Total | 2229.1 | 0 | ||||
Deferred Income Tax | 1312.7 | 2187.5 | 2099.9 | 1733.7 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 16604.5 | 17295.5 | 17808.3 | 18452.4 | 16964.7 |
Cash and Short Term Investments | 3051.4 | 3271.2 | 3825.3 | 3908.6 | 2568.3 |
Cash & Equivalents | 3002.4 | 3220 | 3788.2 | 3818.5 | 2459.2 |
Short Term Investments | 49 | 51.2 | 37.1 | 90.1 | 109.1 |
Total Receivables, Net | 6658.6 | 6902.8 | 7025 | 8127.2 | 7805.7 |
Accounts Receivable - Trade, Net | 5592.8 | 5829.4 | 5914.3 | 6672.8 | 6322.5 |
Total Inventory | 3660.8 | 3824.9 | 3907.4 | 3886 | 3893 |
Prepaid Expenses | 3233.7 | 3296.6 | 3050.6 | 2530.6 | 2697.7 |
Total Assets | 46838.3 | 47809 | 48187 | 48806 | 46919.3 |
Property/Plant/Equipment, Total - Net | 8630.1 | 8855.5 | 8920.4 | 8985.1 | 9102.7 |
Property/Plant/Equipment, Total - Gross | 18273.5 | 18697.7 | 18883.2 | 18961.8 | 19241 |
Accumulated Depreciation, Total | -9643.4 | -9842.2 | -9962.8 | -9976.7 | -10138.3 |
Goodwill, Net | 3877.4 | 3884.2 | 3884.1 | 3892 | 3892 |
Intangibles, Net | 8087.8 | 7985.4 | 7887.7 | 7691.9 | 7482.4 |
Long Term Investments | 3232.4 | 3474.9 | 3350.5 | 3212.6 | 2727.3 |
Other Long Term Assets, Total | 6406.1 | 6313.5 | 6336 | 6572 | 6750.2 |
Total Current Liabilities | 11714.2 | 15093.2 | 13682 | 15052.7 | 13386 |
Accounts Payable | 1639.6 | 1597.8 | 1566.8 | 1670.6 | 1433.3 |
Accrued Expenses | 649.9 | 755.5 | 836.6 | 958.1 | 693.1 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 4.9 | 1778.5 | 1563 | 1538.3 | 1355.9 |
Other Current Liabilities, Total | 9419.8 | 10961.4 | 9715.6 | 10885.7 | 9903.7 |
Total Liabilities | 39939.6 | 41364.6 | 40430 | 39826.8 | 37588.5 |
Total Long Term Debt | 16199.6 | 14736.6 | 15522.4 | 15346.4 | 15152.9 |
Long Term Debt | 16199.6 | 14736.6 | 15522.4 | 15346.4 | 15152.9 |
Deferred Income Tax | 2200.6 | 1857.3 | 1632.5 | 1733.7 | 1286.1 |
Minority Interest | 200.6 | 219.1 | 197.1 | 175.6 | 131.2 |
Other Liabilities, Total | 9624.6 | 9458.4 | 9396 | 7518.4 | 7632.3 |
Total Equity | 6898.7 | 6444.4 | 7757 | 8979.2 | 9330.8 |
Common Stock | 599.7 | 598.1 | 598.2 | 596.3 | 594.1 |
Additional Paid-In Capital | 6579.2 | 6669.2 | 6758 | 6833.4 | 6656.3 |
Retained Earnings (Accumulated Deficit) | 9181.3 | 8530.1 | 9639.4 | 8958.5 | 9369.4 |
Treasury Stock - Common | -52.7 | -52.7 | -52.7 | -52.7 | -50.5 |
Unrealized Gain (Loss) | 4.5 | 9.1 | 6.8 | 3.7 | -18.1 |
Other Equity, Total | -9413.3 | -9309.4 | -9192.7 | -7360 | -7220.4 |
Total Liabilities & Shareholders’ Equity | 46838.3 | 47809 | 48187 | 48806 | 46919.3 |
Total Common Shares Outstanding | 959.019 | 956.575 | 956.589 | 953.653 | 950.155 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Net income/Starting Line | 2737.6 | -204.1 | 3232 | 8318.4 | 6193.7 | 5581.7 |
Cash From Operating Activities | 4851 | 5615.6 | 5524.5 | 4836.6 | 6499.6 | 7260.7 |
Cash From Operating Activities | 1496.6 | 1567.3 | 1609 | 1232.6 | 1323.9 | 1547.6 |
Deferred Taxes | 439.5 | -787.9 | 326.8 | 62.4 | -134.5 | -802.3 |
Non-Cash Items | 661.4 | 1835.4 | 2735.4 | -3089.6 | -136.1 | 1956.3 |
Cash Taxes Paid | 700.6 | 246.5 | 1101.5 | 1180.5 | 954.6 | 1598.8 |
Cash Interest Paid | 146.4 | 192.7 | 223.8 | 305.5 | 345.8 | 338 |
Changes in Working Capital | -484.1 | 3204.9 | -2378.7 | -1687.2 | -747.4 | -1022.6 |
Cash From Investing Activities | -3139.1 | -3783.6 | 1906 | -8082.9 | -2258.9 | -2762.3 |
Capital Expenditures | -1092 | -2163.6 | -3018.2 | -1353.5 | -2029.1 | -1873.2 |
Other Investing Cash Flow Items, Total | -2047.1 | -1620 | 4924.2 | -6729.4 | -229.8 | -889.1 |
Cash From Financing Activities | -559.8 | 142.6 | -5904.9 | -2324.5 | -3137.1 | -4131.3 |
Financing Cash Flow Items | -300.8 | -364.4 | -372.8 | -200.1 | -241.6 | -295.9 |
Total Cash Dividends Paid | -2158.5 | -2192.1 | -2311.8 | -2409.8 | -2687.1 | -3086.8 |
Issuance (Retirement) of Stock, Net | -600.1 | -299.8 | -2491 | -4400 | -500 | -1250 |
Issuance (Retirement) of Debt, Net | 2499.6 | 2998.9 | -729.3 | 4685.4 | 291.6 | 501.4 |
Foreign Exchange Effects | -236.4 | -20.5 | -63.6 | -89.9 | 216 | -205.7 |
Net Change in Cash | 915.7 | 1954.1 | 1462 | -5660.7 | 1319.6 | 161.4 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 1355.3 | 2745.5 | 3855.6 | 5581.7 | 1902.9 |
Cash From Operating Activities | 1697.4 | 3472.9 | 5104.2 | 7260.7 | 2499.2 |
Cash From Operating Activities | 350.3 | 719.6 | 1101.9 | 1547.6 | 435.7 |
Deferred Taxes | -119.1 | -413.8 | -709.8 | -802.3 | -506.6 |
Non-Cash Items | 213.7 | 303.2 | 1404.6 | 1956.3 | 712.7 |
Changes in Working Capital | -102.8 | 118.4 | -548.1 | -1022.6 | -45.5 |
Cash From Investing Activities | -1283.5 | -1766.8 | -2383.3 | -2762.3 | -1013.8 |
Capital Expenditures | -492.1 | -1023.4 | -1479 | -1873.2 | -857.2 |
Other Investing Cash Flow Items, Total | -791.4 | -743.4 | -904.3 | -889.1 | -156.6 |
Cash From Financing Activities | -1058.4 | -2141.6 | -2604.8 | -4131.3 | -2878.3 |
Financing Cash Flow Items | -279.9 | -294.8 | -295.3 | -295.9 | -282.4 |
Total Cash Dividends Paid | -774.8 | -1543.1 | -2313.5 | -3086.8 | -885.5 |
Issuance (Retirement) of Stock, Net | 0 | -500 | -500 | -1250 | -1500 |
Issuance (Retirement) of Debt, Net | -3.7 | 196.3 | 504 | 501.4 | -210.4 |
Foreign Exchange Effects | -10.2 | -1.6 | 15 | -205.7 | 33.6 |
Net Change in Cash | -654.7 | -437.1 | 131.1 | 161.4 | -1359.3 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Lilly Endowment, Inc. | Investment Advisor | 10.8347 | 102948810 | -210000 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 7.6008 | 72221213 | 994066 | 2022-09-30 | LOW |
PNC Wealth Management | Investment Advisor | 5.4451 | 51738161 | -44061 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.2364 | 40253792 | 58949 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 3.5343 | 33582472 | 168444 | 2022-09-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 3.3604 | 31929656 | 631015 | 2022-09-30 | LOW |
Capital World Investors | Investment Advisor | 3.0547 | 29024874 | 282228 | 2022-09-30 | LOW |
PRIMECAP Management Company | Investment Advisor | 2.9486 | 28017155 | -421333 | 2022-09-30 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 2.5054 | 23805927 | 3379269 | 2022-09-30 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 2.2989 | 21843288 | -1593968 | 2022-09-30 | LOW |
State Farm Insurance Companies | Insurance Company | 1.8324 | 17410725 | 0 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.6935 | 16091249 | 373938 | 2022-09-30 | LOW |
Jennison Associates LLC | Investment Advisor/Hedge Fund | 1.0592 | 10064742 | -293324 | 2022-09-30 | LOW |
JP Morgan Asset Management | Investment Advisor | 0.866 | 8228610 | 173535 | 2022-09-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.8435 | 8014500 | -246196 | 2021-12-31 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7439 | 7068030 | -132558 | 2022-09-30 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.6244 | 5933104 | -307204 | 2022-09-30 | LOW |
Capital International Investors | Investment Advisor | 0.5893 | 5599174 | 637189 | 2022-09-30 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.5885 | 5591703 | -216451 | 2022-09-30 | LOW |
BofA Global Research (US) | Research Firm | 0.5868 | 5576096 | -144521 | 2022-09-30 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com GroupTraders
Active clients monthly
Monthly investing volume
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Eli Lilly Company profile
Eli Lilly and Company is engaged in the drug manufacturing business. The company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. Explore the Eli Lilly stock at Capital.com. Monitor Lilly shares in real time. With our website you can stay updated on Lilly share price.
Industry: | Pharmaceuticals (NEC) |
Lilly Corporate Ctr
Drop Code 1094
INDIANAPOLIS
INDIANA 46285-0001
US
Income Statement
- Annual
- Quarterly
News

S&P 500 & DAX 40 Forecast for the Week Ahead
S&P 500 builds higher after Fed meeting, DAX 40 runs into resistance
16:30, 3 February 2023
FX Weekly Outlook: USD, GBP/USD, USD/JPY Analysis
USD, GBP/USD, USD/JPY forecasts for the week ahead.
15:56, 3 February 2023
GBP/USD drops below 1.23 as BOE comments suggest possible end of rate hikes
Despite increasing rates by 50bps at their February meeting, the messaging from the BOE suggests a dovish tilt an the possible end of rate hikes.
15:37, 2 February 2023
Gold latest: XAU/USD rallies on Fed meeting as traders eye Friday’s jobs data
Gold buyers take advantage of risk on sentiment as they eye Friday's NFP data to assess the likelihood of a soft landing
11:48, 2 February 2023
British Pound (GBP) Outlook: GBP/USD, EUR/GBP Ahead of BoE Rate Decision
Bank of England remains a dovish hiker. GBP at risk of another dovish twist
15:13, 1 February 2023People also watch
Still looking for a broker you can trust?
Join the 480.000+ traders worldwide that chose to trade with Capital.com